GLiPtest
New member
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-staff-highlights-peptide-risks-says-little-evidence-benefits-2026-06-30/
If anyone watched the video of the compounding advisory committee meeting where peptides long in use by 503a/b pharmacies were under consideration for a de facto ban, nearly every speaker, and those in attendance were against the restrictions being imposed. The committee had a very hostile crowd and voted to impose restrictions on peptides nonetheless.